Key Points Eli Lilly dominates the weight loss drug market -- one set to approach $100 billion in a few years. Lilly and rival Novo Nordisk launched weight loss pills this year, and so far, Novo is leading in prescriptions. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE:LLY) is the global leader in one of the hottest growth markets on the planet: the weight loss drug market. The pharma giant holds 60% of the U.S. market, while its closest rival, Novo Nordisk (NYSE:NVO) , has about 38% share. Until this year, this market included only injectable drugs from these companies, and the names are quite recognizable. Lilly is the maker of Mounjaro and Zepbound, while Novo makes Ozempic and Wegovy.
Головну думку ми показуємо публічно. Створіть безкоштовний акаунт, щоб читати повну статтю, зберігати її, обговорювати та поєднувати з ринковим і OSINT-контекстом.